Randomized Phase 2 trial of Isatuximab during Autologous Stem Cell Collection and Transplantation Period in patients with Multiple Myeloma and Lymphoma

The purpose of this study is to see if Isatuximab can alter the immune system favorably in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. This study will have two arms. On one arm (control arm), Participants will receive standard transplant procedures and on the other arm (experimental arm), Participants will receive Isatuximab in addition to the standard transplant procedures. The assignment to these arms is done randomly (determined by chance, like flipping a coin) by a computer. Each Participant will have about 66% chance of getting on the experimental arm and about 33% chance of getting on the control arm.

Are you Eligible? (Inclusion Criteria)

• Inclusion Criteria
• • Are you 18 years of age or older?
• • History of Multiple Myeloma and Undergoing stem cell transplant
• • Relapsed Hodgkin’s disease and Undergoing stem cell transplant
• • Non-Hodgkin’s Lymphomas and Undergoing stem cell transplant